Psoriatic Arthritis – Epidemiology – Europe
Clarivate Epidemiology’s coverage of psoriatic arthritis (PsA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s PsA forecast will answer the following questions:
- Of all people with PsA, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with PsA, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts six PsA patient populations, as follows:
- Total PsA prevalent cases.
- Diagnosed PsA prevalent cases.
- Diagnosed PsA drug-treated prevalent cases.
- Diagnosed PsA prevalent cases with peripheral joint involvement.
- Diagnosed PsA prevalent cases with axial joint involvement.
- Diagnosed PsA prevalent cases with mixed joint involvement.
Note: Coverage may vary by country.
